Skip to main content

Table 1 Demographic and clinical details of RA participants

From: Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study

 

Biologic-naïve patients(a)

TNFi-treated patients(b)

p-value

 

n = 803

n = 2154

 

Female, n (%)

567 (70.6)

1582 (73.4)

0.12*

Age in yrs, mean (SD)

61.2 (12.3)

55.6 (125)

<0.001**

Rheumatoid factor positive(c), n (%)

465/547 (85.0)

1073/1326 (80.9)

0.04*

No. of prior DMARDs, mean (SD)

2.5 (1.8)

4.0 (2.0)

<0.001**

Ever used methotrexate, n (%)

614 (76.5)

1851 (85.9)

<0.001*

Ever used prednisolone, n (%)

452 (56.3)

1899 (88.2)

<0.001*

HAQ score, mean (SD)

1.16 (0.79)

1.37 (0.73)

<0.001**

(range 0–3, 0 = no disability)

AQoL score, mean (SD)

0.53 (0.27)

0.49 (0.24)

<0.001**

(range 0–1, 1 = full health)

Joint count, median (range)

14.5 (0, 59) (n = 286)

24 (0, 72) (n = 906)

<0.001***

ESR mm/h, median (range)

26 (1, 129) (n = 263)

29 (0, 134) (n = 834)

0.07***

CRP mg/L (median, range)

8.5 (0.4, 161) (n = 264)

17 (0.1, 206) (n = 836)

<0.001***

Current smoker, n (%)

90/776 (11.6)

300/2111 (14.2)

0.07*

Years since RA diagnosis, mean (SD)

13.0 (11.3)

13.7 (10.5)

0.12**

Prior malignancies(d), n (%)

61 (7.6 %)

72 (3.3 %)

<0.001*

  1. (a) data from time first entered into registry unless otherwise indicated; (b) data from time first commenced TNFi treatment; (c) data incomplete: n is shown in table; (d) verified malignancies (excluding NMSC and in-situ cancers) recorded prior to commencement of the study period. HAQ health assessment questionnaire, AQoL assessment of quality of life; ESR erythrocyte sedimentation rate, CRP C-reactive protein.* p-value from Chi-squared test; ** p-value from t-test; *** p-value from Wilcoxon Rank Sum test